RxDoctor Payments Data

Jose Fournier Rebollo, MD

Urology · Bayamon, PRNPI 1750484143

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,684 of the $3,469 with a category attached, or 77.4%. 9 manufacturers reported payments, led by Neotract Inc. at 30.3% of the total. Reporting peaked in 2019 at $1,851 and has fallen 71.7% since, to $524 in 2025.

$3,469in general payments, 2019–2025

Across 34 payments — averaging $102.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • Boston Scientific$685
  • Ferring Pharmaceuticals Inc.$532
  • Verity Pharmaceuticals Inc.$365
  • Johnson & Johnson$268
  • Travere Therapeutics, Inc.$236
  • plus $332 from 3 others

What the payments were for

  • Travel & lodging$61118%
  • Food & beverage$2,68477%
  • Education$1745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,469 in reported general payments places this provider in the 60th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,676
Medicare patients
29
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate11$66,668
TrelstarTriptorelin Pamoate21$53,622
FirmagonDegarelix Acetate81$42,259
MyrbetriqMirabegron24$16,293
Silodosin144$10,187
Trospium Chloride ErTrospium Chloride53$9,438
Tamsulosin Hcl594$8,884
PremarinEstrogens, Conjugated18$7,999
Potassium Citrate ErPotassium Citrate83$6,028
Tolterodine Tartrate ErTolterodine Tartrate59$4,813
Tadalafil23$4,528
Dutasteride121$4,324
Testosterone Cypionate95$3,458
Oxybutynin Chloride ErOxybutynin Chloride132$3,341
Finasteride188$3,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Verity Pharmaceuticals Inc.Trelstar$365$53,62221 claims
Ferring Pharmaceuticals Inc.Firmagon$532$42,25981 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 122 urology providers in Puerto Rico.

Other urology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →